Cargando…

Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China

Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application. At present, tyrosine receptor kinase (TRK) inhibitors targeting neurotrophic tyrosine receptor kinase (NTRK) gene fusions are among the fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chunwei, Si, Lu, Wang, Wenxian, Li, Ziming, Song, Zhengbo, Wang, Qian, Liu, Aijun, Yu, Jinpu, Fang, Wenfeng, Zhong, Wenzhao, Wang, Zhijie, Zhang, Yongchang, Liu, Jingjing, Zhang, Shirong, Cai, Xiuyu, Liu, Anwen, Li, Wen, Zhan, Ping, Liu, Hongbing, Lv, Tangfeng, Miao, Liyun, Min, Lingfeng, Chen, Yu, Yuan, Jingping, Wang, Feng, Jiang, Zhansheng, Lin, Gen, Pu, Xingxiang, Lin, Rongbo, Liu, Weifeng, Rao, Chuangzhou, Lv, Dongqing, Yu, Zongyang, Lei, Lei, Li, Xiaoyan, Tang, Chuanhao, Zhou, Chengzhi, Zhang, Junping, Xue, Junli, Guo, Hui, Chu, Qian, Meng, Rui, Wu, Jingxun, Zhang, Rui, Hu, Xiao, Zhou, Jin, Zhu, Zhengfei, Li, Yongheng, Qiu, Hong, Xia, Fan, Lu, Yuanyuan, Chen, Xiaofeng, Ge, Rui, Dai, Enyong, Han, Yu, Pan, Weiwei, Luo, Jiancheng, Jia, Hongtao, Dong, Xiaowei, Pang, Fei, Wang, Kai, Wang, Liping, Zhu, Youcai, Xie, Yanru, Lin, Xinqin, Cai, Jing, Wei, Jia, Lan, Fen, Feng, Huijing, Wang, Lin, Du, Yingying, Yao, Wang, Shi, Xuefei, Niu, Xiaomin, Yuan, Dongmei, Yao, Yanwen, Huang, Jianhui, Zhang, Yinbin, Sun, Pingli, Wang, Hong, Ye, Mingxiang, Wang, Dong, Wang, Zhaofeng, Wan, Bing, Lv, Donglai, Wei, Qing, Kang, Jin, Zhang, Jiatao, Zhang, Chao, Yu, Genhua, Ou, Juanjuan, Shi, Lin, Li, Zhongwu, Liu, Zhefeng, Liu, Jing, Yang, Nong, Wu, Lin, Wang, Huijuan, Jin, Gu, Yang, Liu, Wang, Guansong, Fang, Meiyu, Fang, Yong, Li, Yuan, Wang, Xiaojia, Zhang, Yiping, Ma, Shenglin, Wang, Biyun, Zhang, Xiaotian, Song, Yong, Lu, Yuanzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626341/
https://www.ncbi.nlm.nih.gov/pubmed/36127731
http://dx.doi.org/10.1111/1759-7714.14644
_version_ 1784822709833695232
author Xu, Chunwei
Si, Lu
Wang, Wenxian
Li, Ziming
Song, Zhengbo
Wang, Qian
Liu, Aijun
Yu, Jinpu
Fang, Wenfeng
Zhong, Wenzhao
Wang, Zhijie
Zhang, Yongchang
Liu, Jingjing
Zhang, Shirong
Cai, Xiuyu
Liu, Anwen
Li, Wen
Zhan, Ping
Liu, Hongbing
Lv, Tangfeng
Miao, Liyun
Min, Lingfeng
Chen, Yu
Yuan, Jingping
Wang, Feng
Jiang, Zhansheng
Lin, Gen
Pu, Xingxiang
Lin, Rongbo
Liu, Weifeng
Rao, Chuangzhou
Lv, Dongqing
Yu, Zongyang
Lei, Lei
Li, Xiaoyan
Tang, Chuanhao
Zhou, Chengzhi
Zhang, Junping
Xue, Junli
Guo, Hui
Chu, Qian
Meng, Rui
Wu, Jingxun
Zhang, Rui
Hu, Xiao
Zhou, Jin
Zhu, Zhengfei
Li, Yongheng
Qiu, Hong
Xia, Fan
Lu, Yuanyuan
Chen, Xiaofeng
Ge, Rui
Dai, Enyong
Han, Yu
Pan, Weiwei
Luo, Jiancheng
Jia, Hongtao
Dong, Xiaowei
Pang, Fei
Wang, Kai
Wang, Liping
Zhu, Youcai
Xie, Yanru
Lin, Xinqin
Cai, Jing
Wei, Jia
Lan, Fen
Feng, Huijing
Wang, Lin
Du, Yingying
Yao, Wang
Shi, Xuefei
Niu, Xiaomin
Yuan, Dongmei
Yao, Yanwen
Huang, Jianhui
Zhang, Yinbin
Sun, Pingli
Wang, Hong
Ye, Mingxiang
Wang, Dong
Wang, Zhaofeng
Wan, Bing
Lv, Donglai
Wei, Qing
Kang, Jin
Zhang, Jiatao
Zhang, Chao
Yu, Genhua
Ou, Juanjuan
Shi, Lin
Li, Zhongwu
Liu, Zhefeng
Liu, Jing
Yang, Nong
Wu, Lin
Wang, Huijuan
Jin, Gu
Yang, Liu
Wang, Guansong
Fang, Meiyu
Fang, Yong
Li, Yuan
Wang, Xiaojia
Zhang, Yiping
Ma, Shenglin
Wang, Biyun
Zhang, Xiaotian
Song, Yong
Lu, Yuanzhi
author_facet Xu, Chunwei
Si, Lu
Wang, Wenxian
Li, Ziming
Song, Zhengbo
Wang, Qian
Liu, Aijun
Yu, Jinpu
Fang, Wenfeng
Zhong, Wenzhao
Wang, Zhijie
Zhang, Yongchang
Liu, Jingjing
Zhang, Shirong
Cai, Xiuyu
Liu, Anwen
Li, Wen
Zhan, Ping
Liu, Hongbing
Lv, Tangfeng
Miao, Liyun
Min, Lingfeng
Chen, Yu
Yuan, Jingping
Wang, Feng
Jiang, Zhansheng
Lin, Gen
Pu, Xingxiang
Lin, Rongbo
Liu, Weifeng
Rao, Chuangzhou
Lv, Dongqing
Yu, Zongyang
Lei, Lei
Li, Xiaoyan
Tang, Chuanhao
Zhou, Chengzhi
Zhang, Junping
Xue, Junli
Guo, Hui
Chu, Qian
Meng, Rui
Wu, Jingxun
Zhang, Rui
Hu, Xiao
Zhou, Jin
Zhu, Zhengfei
Li, Yongheng
Qiu, Hong
Xia, Fan
Lu, Yuanyuan
Chen, Xiaofeng
Ge, Rui
Dai, Enyong
Han, Yu
Pan, Weiwei
Luo, Jiancheng
Jia, Hongtao
Dong, Xiaowei
Pang, Fei
Wang, Kai
Wang, Liping
Zhu, Youcai
Xie, Yanru
Lin, Xinqin
Cai, Jing
Wei, Jia
Lan, Fen
Feng, Huijing
Wang, Lin
Du, Yingying
Yao, Wang
Shi, Xuefei
Niu, Xiaomin
Yuan, Dongmei
Yao, Yanwen
Huang, Jianhui
Zhang, Yinbin
Sun, Pingli
Wang, Hong
Ye, Mingxiang
Wang, Dong
Wang, Zhaofeng
Wan, Bing
Lv, Donglai
Wei, Qing
Kang, Jin
Zhang, Jiatao
Zhang, Chao
Yu, Genhua
Ou, Juanjuan
Shi, Lin
Li, Zhongwu
Liu, Zhefeng
Liu, Jing
Yang, Nong
Wu, Lin
Wang, Huijuan
Jin, Gu
Yang, Liu
Wang, Guansong
Fang, Meiyu
Fang, Yong
Li, Yuan
Wang, Xiaojia
Zhang, Yiping
Ma, Shenglin
Wang, Biyun
Zhang, Xiaotian
Song, Yong
Lu, Yuanzhi
author_sort Xu, Chunwei
collection PubMed
description Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application. At present, tyrosine receptor kinase (TRK) inhibitors targeting neurotrophic tyrosine receptor kinase (NTRK) gene fusions are among the first “tumor agnostic” drugs approved for pan‐cancer use. Representative TRK inhibitors, including larotrectinib and entrectinib, have shown high efficacy for many types of cancer. At the same time, several second‐generation drugs designed to overcome first‐generation drug resistance are undergoing clinical development. Due to the rarity of NTRK gene fusions in common cancer types and technical issues regarding the complexity of fusion patterns, effectively screening patients for TRK inhibitor treatment in routine clinical practice is challenging. Different detection methods including immunohistochemistry, fluorescence in situ hybridization, reverse transcription‐polymerase chain reaction, and (DNA and/or RNA‐based) next‐generation sequencing have pros and cons. As such, recommending suitable tests for individual patients and ensuring the quality of tests is essential. Moreover, at present, there is a lack of systematic review for the clinical efficacy and development status of first‐ and second‐generation TRK inhibitors. To resolve the above issues, our expert group has reached a consensus regarding the diagnosis and treatment of NTRK gene fusion solid tumors, aiming to standardize clinical practice with the goal of benefiting patients with NTRK gene fusions treated with TRK inhibitors.
format Online
Article
Text
id pubmed-9626341
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-96263412022-11-03 Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China Xu, Chunwei Si, Lu Wang, Wenxian Li, Ziming Song, Zhengbo Wang, Qian Liu, Aijun Yu, Jinpu Fang, Wenfeng Zhong, Wenzhao Wang, Zhijie Zhang, Yongchang Liu, Jingjing Zhang, Shirong Cai, Xiuyu Liu, Anwen Li, Wen Zhan, Ping Liu, Hongbing Lv, Tangfeng Miao, Liyun Min, Lingfeng Chen, Yu Yuan, Jingping Wang, Feng Jiang, Zhansheng Lin, Gen Pu, Xingxiang Lin, Rongbo Liu, Weifeng Rao, Chuangzhou Lv, Dongqing Yu, Zongyang Lei, Lei Li, Xiaoyan Tang, Chuanhao Zhou, Chengzhi Zhang, Junping Xue, Junli Guo, Hui Chu, Qian Meng, Rui Wu, Jingxun Zhang, Rui Hu, Xiao Zhou, Jin Zhu, Zhengfei Li, Yongheng Qiu, Hong Xia, Fan Lu, Yuanyuan Chen, Xiaofeng Ge, Rui Dai, Enyong Han, Yu Pan, Weiwei Luo, Jiancheng Jia, Hongtao Dong, Xiaowei Pang, Fei Wang, Kai Wang, Liping Zhu, Youcai Xie, Yanru Lin, Xinqin Cai, Jing Wei, Jia Lan, Fen Feng, Huijing Wang, Lin Du, Yingying Yao, Wang Shi, Xuefei Niu, Xiaomin Yuan, Dongmei Yao, Yanwen Huang, Jianhui Zhang, Yinbin Sun, Pingli Wang, Hong Ye, Mingxiang Wang, Dong Wang, Zhaofeng Wan, Bing Lv, Donglai Wei, Qing Kang, Jin Zhang, Jiatao Zhang, Chao Yu, Genhua Ou, Juanjuan Shi, Lin Li, Zhongwu Liu, Zhefeng Liu, Jing Yang, Nong Wu, Lin Wang, Huijuan Jin, Gu Yang, Liu Wang, Guansong Fang, Meiyu Fang, Yong Li, Yuan Wang, Xiaojia Zhang, Yiping Ma, Shenglin Wang, Biyun Zhang, Xiaotian Song, Yong Lu, Yuanzhi Thorac Cancer Clinical Guideline Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application. At present, tyrosine receptor kinase (TRK) inhibitors targeting neurotrophic tyrosine receptor kinase (NTRK) gene fusions are among the first “tumor agnostic” drugs approved for pan‐cancer use. Representative TRK inhibitors, including larotrectinib and entrectinib, have shown high efficacy for many types of cancer. At the same time, several second‐generation drugs designed to overcome first‐generation drug resistance are undergoing clinical development. Due to the rarity of NTRK gene fusions in common cancer types and technical issues regarding the complexity of fusion patterns, effectively screening patients for TRK inhibitor treatment in routine clinical practice is challenging. Different detection methods including immunohistochemistry, fluorescence in situ hybridization, reverse transcription‐polymerase chain reaction, and (DNA and/or RNA‐based) next‐generation sequencing have pros and cons. As such, recommending suitable tests for individual patients and ensuring the quality of tests is essential. Moreover, at present, there is a lack of systematic review for the clinical efficacy and development status of first‐ and second‐generation TRK inhibitors. To resolve the above issues, our expert group has reached a consensus regarding the diagnosis and treatment of NTRK gene fusion solid tumors, aiming to standardize clinical practice with the goal of benefiting patients with NTRK gene fusions treated with TRK inhibitors. John Wiley & Sons Australia, Ltd 2022-09-20 2022-11 /pmc/articles/PMC9626341/ /pubmed/36127731 http://dx.doi.org/10.1111/1759-7714.14644 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Guideline
Xu, Chunwei
Si, Lu
Wang, Wenxian
Li, Ziming
Song, Zhengbo
Wang, Qian
Liu, Aijun
Yu, Jinpu
Fang, Wenfeng
Zhong, Wenzhao
Wang, Zhijie
Zhang, Yongchang
Liu, Jingjing
Zhang, Shirong
Cai, Xiuyu
Liu, Anwen
Li, Wen
Zhan, Ping
Liu, Hongbing
Lv, Tangfeng
Miao, Liyun
Min, Lingfeng
Chen, Yu
Yuan, Jingping
Wang, Feng
Jiang, Zhansheng
Lin, Gen
Pu, Xingxiang
Lin, Rongbo
Liu, Weifeng
Rao, Chuangzhou
Lv, Dongqing
Yu, Zongyang
Lei, Lei
Li, Xiaoyan
Tang, Chuanhao
Zhou, Chengzhi
Zhang, Junping
Xue, Junli
Guo, Hui
Chu, Qian
Meng, Rui
Wu, Jingxun
Zhang, Rui
Hu, Xiao
Zhou, Jin
Zhu, Zhengfei
Li, Yongheng
Qiu, Hong
Xia, Fan
Lu, Yuanyuan
Chen, Xiaofeng
Ge, Rui
Dai, Enyong
Han, Yu
Pan, Weiwei
Luo, Jiancheng
Jia, Hongtao
Dong, Xiaowei
Pang, Fei
Wang, Kai
Wang, Liping
Zhu, Youcai
Xie, Yanru
Lin, Xinqin
Cai, Jing
Wei, Jia
Lan, Fen
Feng, Huijing
Wang, Lin
Du, Yingying
Yao, Wang
Shi, Xuefei
Niu, Xiaomin
Yuan, Dongmei
Yao, Yanwen
Huang, Jianhui
Zhang, Yinbin
Sun, Pingli
Wang, Hong
Ye, Mingxiang
Wang, Dong
Wang, Zhaofeng
Wan, Bing
Lv, Donglai
Wei, Qing
Kang, Jin
Zhang, Jiatao
Zhang, Chao
Yu, Genhua
Ou, Juanjuan
Shi, Lin
Li, Zhongwu
Liu, Zhefeng
Liu, Jing
Yang, Nong
Wu, Lin
Wang, Huijuan
Jin, Gu
Yang, Liu
Wang, Guansong
Fang, Meiyu
Fang, Yong
Li, Yuan
Wang, Xiaojia
Zhang, Yiping
Ma, Shenglin
Wang, Biyun
Zhang, Xiaotian
Song, Yong
Lu, Yuanzhi
Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
title Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
title_full Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
title_fullStr Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
title_full_unstemmed Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
title_short Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China
title_sort expert consensus on the diagnosis and treatment of ntrk gene fusion solid tumors in china
topic Clinical Guideline
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626341/
https://www.ncbi.nlm.nih.gov/pubmed/36127731
http://dx.doi.org/10.1111/1759-7714.14644
work_keys_str_mv AT xuchunwei expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT silu expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wangwenxian expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT liziming expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT songzhengbo expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wangqian expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT liuaijun expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT yujinpu expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT fangwenfeng expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhongwenzhao expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wangzhijie expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhangyongchang expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT liujingjing expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhangshirong expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT caixiuyu expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT liuanwen expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT liwen expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhanping expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT liuhongbing expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT lvtangfeng expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT miaoliyun expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT minlingfeng expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT chenyu expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT yuanjingping expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wangfeng expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT jiangzhansheng expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT lingen expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT puxingxiang expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT linrongbo expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT liuweifeng expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT raochuangzhou expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT lvdongqing expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT yuzongyang expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT leilei expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT lixiaoyan expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT tangchuanhao expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhouchengzhi expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhangjunping expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT xuejunli expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT guohui expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT chuqian expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT mengrui expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wujingxun expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhangrui expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT huxiao expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhoujin expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhuzhengfei expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT liyongheng expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT qiuhong expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT xiafan expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT luyuanyuan expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT chenxiaofeng expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT gerui expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT daienyong expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT hanyu expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT panweiwei expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT luojiancheng expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT jiahongtao expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT dongxiaowei expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT pangfei expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wangkai expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wangliping expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhuyoucai expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT xieyanru expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT linxinqin expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT caijing expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT weijia expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT lanfen expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT fenghuijing expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wanglin expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT duyingying expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT yaowang expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT shixuefei expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT niuxiaomin expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT yuandongmei expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT yaoyanwen expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT huangjianhui expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhangyinbin expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT sunpingli expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wanghong expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT yemingxiang expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wangdong expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wangzhaofeng expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wanbing expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT lvdonglai expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT weiqing expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT kangjin expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhangjiatao expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhangchao expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT yugenhua expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT oujuanjuan expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT shilin expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT lizhongwu expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT liuzhefeng expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT liujing expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT yangnong expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wulin expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wanghuijuan expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT jingu expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT yangliu expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wangguansong expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT fangmeiyu expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT fangyong expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT liyuan expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wangxiaojia expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhangyiping expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT mashenglin expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT wangbiyun expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT zhangxiaotian expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT songyong expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina
AT luyuanzhi expertconsensusonthediagnosisandtreatmentofntrkgenefusionsolidtumorsinchina